Neal G. Koller
President & Chief Executive Officer
President & Chief Executive Officer
- 3724a Thomas Point Road
Annapolis, Maryland 21403
USA
Tel: +1 443 994 0101
Fax: +1 410 990 9817
nkoller@plurogen.com
| PluroGen Therapeutics, Inc. 503 Broadleaf Way Charlottesville, Virginia 22911 USA Tel: +1 443 994 0101 Fax: +1 410 990 9817 www.plurogen.com |
December 18, 2006
Dear Investor:
We hope everything is well and you are heading into a very happy holiday season.
Thank you for your investment and trust in PluroGen™. As a result of your commitment, we have been able to achieve
the following significant milestones since the company’s incorporation at the end of January 2006.
We have moved the company forward and achieved much in a very short period of time. Thank you for your support.
In a separate letter we will provide you with an update on fund raising. Should you have any questions or want to talk
please let us know. Thank you again for your continued support. We will keep you posted on our progress in 2007.
Happy holidays.
Neal G. Koller
NGK/sa
Dear Investor:
We hope everything is well and you are heading into a very happy holiday season.
Thank you for your investment and trust in PluroGen™. As a result of your commitment, we have been able to achieve
the following significant milestones since the company’s incorporation at the end of January 2006.
- Completed Business Plan, 1st round Offering Memorandum Package & 1st Amendment to the Offering
- Completed Support Documentation for Business Plan & Offering Memorandum
- Hired world class President & CEO, Neal Koller
- Contracted world class VP Medical & Scientific Affairs, Glenn Warden, MD, MBA, FACS
- o A globally Recognized Burn Surgeon & Medical Researcher
- Assembled Industry Expert Commercial Advisory Board
- Assembled World Class Scientific Advisory Board
- Raised $1.45M
- Contracted Global R&D /Regulatory /Clinical Trial Partner (& Investor) - Cato Research, Inc. (13 offices
worldwide)
- o Drafted Product Regulatory, Clinical & Manufacturing Plan
o Completed 1st Meeting with FDA – October 5, 2006
- - Confirmed strategy for fast-track Regulatory Path
- FDA agreed PluroGen is ready for Phase III clinical trial for our 1st product
- Launched Web Site
- Located R&D Space & Began Search for Potential R&D Personnel
- Hired Accounting Firm
- Hired Law Firm
- Hired Intellectual Property Firm
- o Expansion of Patent Portfolio Underway
- Initiated Discussions with Potential Commercial Partners
- Signed agreement with Globally Recognized Contract Manufacturing Partner
- o Manufacturing Scale & Compliance with FDA Requirements Underway
We have moved the company forward and achieved much in a very short period of time. Thank you for your support.
In a separate letter we will provide you with an update on fund raising. Should you have any questions or want to talk
please let us know. Thank you again for your continued support. We will keep you posted on our progress in 2007.
Happy holidays.
Neal G. Koller
NGK/sa